Melphalan Injection

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Hospital das Clínicas de Ribeirão Preto

Conditions

Large B-cell LymphomaUveal Melanoma

Phase 1

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

CompletedNCT04690192

Institute of Hematology & Blood Diseases Hospital, ChinaLarge B-cell Lymphoma

Start: 2021-01-01End: 2024-12-30Updated: 2025-05-13

Melphalan Chemoreduction for Ocular Melanoma

Enrolling by invitationNCT05893654

Hospital das Clínicas de Ribeirão PretoUveal Melanoma

Start: 2021-05-01End: 2025-12-31Target: 10Updated: 2025-09-15

Related Papers

Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report

Current Problems in Cancer Case Reports2024-08-08

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Journal for ImmunoTherapy of Cancer2024-04-0125 citations